戴纳基治疗公司宣布，其针对1型强直性肌营养不良症的在研药物Zeleciment Basivarsen（研发代号：Dyne-101）已获得日本厚生劳动省授予的孤儿药认定。此项认定标志着该药物在日本的开发进程迈出了重要一步，为后续的临床研究、审评审批以及潜在的市场准入奠定了基础。孤儿药资格通常能为药物开发者带来诸如税收减免、研发资助以及市场独占期等一系列政策优惠与支持。
戴纳基治疗公司宣布，其针对1型强直性肌营养不良症的在研药物Zeleciment Basivarsen（研发代号：Dyne-101）已获得日本厚生劳动省授予的孤儿药认定。此项认定标志着该药物在日本的开发进程迈出了重要一步，为后续的临床研究、审评审批以及潜在的市场准入奠定了基础。孤儿药资格通常能为药物开发者带来诸如税收减免、研发资助以及市场独占期等一系列政策优惠与支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.